Cantor Fitzgerald Forecasts Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Kura Oncology in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($2.94) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter in the prior year, the firm posted ($0.50) earnings per share.

A number of other equities research analysts also recently weighed in on the stock. UBS Group started coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price on the stock. Jefferies Financial Group dropped their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Wedbush reissued an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research note on Monday, November 4th. HC Wainwright upped their price objective on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, November 21st. Finally, TD Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.38.

Kura Oncology Stock Performance

Shares of KURA opened at $8.21 on Wednesday. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $638.41 million, a PE ratio of -3.48 and a beta of 0.81. The stock has a 50-day moving average price of $9.88 and a 200-day moving average price of $16.09.

Institutional Trading of Kura Oncology

A number of large investors have recently made changes to their positions in KURA. nVerses Capital LLC bought a new stake in shares of Kura Oncology in the third quarter worth about $25,000. Point72 DIFC Ltd purchased a new position in Kura Oncology in the 3rd quarter worth about $146,000. Quarry LP bought a new stake in Kura Oncology during the 2nd quarter valued at about $196,000. Erste Asset Management GmbH purchased a new stake in Kura Oncology in the 3rd quarter valued at about $215,000. Finally, Bellevue Group AG grew its stake in Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after acquiring an additional 3,600 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.